Memorandums of understanding were agreed with German pharmaceutical firm Boehringer Ingelheim and the Danish healthcare company Novo Nordisk at the Riyadh Global Medical Biotechnology Summit earlier this week.

They aim to boost cooperation with the biotech and pharmaceutical sector, localize manufacturing, raise awareness and establish research centers in the Kingdom.

Under its deal, Boehringer Ingelheim will increase the manufacture of medicine used to treat type 2 diabetes and diagnose rare diseases in the Kingdom.

Novo Nordisk Saudi Arabia’s deal with King Abdullah University of Science and Technology will help develop awareness of metabolic disorders, obesity and diabetes.

The agreements were negotiated by the Ministry of Investment, and signed in the presence of Minister of Investment Khalid bin Abdulaziz Al-Faleh. The health summit was organized by the Ministry of National Guard Health Affairs.

SPA